The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than ...
A research team led by the Department of Medicine, under the School of Clinical Medicine, LKS Faculty of Medicine of the ...
GLP-1 receptor agonists show promise beyond obesity but require careful use due to sarcopenia risk and complex effects on mental health.
GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer. HealthDay News — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) seem ...
Compared with unexposed pregnancies, the GLP-1 RA group had a higher risk for excess gestational weight gain, and a higher risk for preterm delivery, gestational diabetes, and hypertensive disorders ...
The use of GLP-1 receptor agonists (GLP-1 RAs) was associated with a lower risk for serious infections — particularly respiratory, skin and soft tissue, musculoskeletal, and vascular infections as ...
Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.
GLP-1 receptor agonists tied to reduced acute asthma exacerbations in teens with overweight, obesity
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in adolescents with overweight or obesity, according to a research letter ...
Stephen has degrees in science (Physics major) and arts (English Literature and the History and Philosophy of Science), as well as a Graduate Diploma in Science Communication. Stephen has degrees in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results